老年AML患者的抗白血病疗法不能接受传统治疗:系统性审查和元分析
Maria Jose Oliveros1, Saifur R Chowdhury1, Yetiani Roldan2
1McMaster University, Hamilton, Ontario, Canada.
Blood advances
|January 15, 2026
概括
患有急性髓性白血病 (AML) 的老年人无法接受标准化疗,可以从venetoclax组合中受益. 在这种人群中,低甲基化剂或低剂量细胞氨基与venetoclax可能会改善生存和缓解.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 患有急性髓性白血病 (AML) 的老年人往往无法接受标准的诱导化疗.
- 尽管最近取得了进展,但这种人群的治疗结果仍然很差.
研究的目的:
- 进行更新的系统审查,以告知2025年美国血液学会 (ASH) 针对老年人的AML指南.
- 为了比较各种治疗的疗效和安全性,老年人与AML不符合常规化疗.
主要方法:
- 随机对照试验 (RCT) 和非随机研究 (NRS) 的系统审查,包括患有AML的55岁以上的成年人.
- 关于死亡率,缓解,生活质量 (QoL),功能状态和严重毒性的证据综合.
- 应用GRADE方法来评估证据的确定性.
主要成果:
- 阿扎西提丁 (AZA) 或低剂量细胞氨基酸 (LDAC) 与维尼托克拉克斯 (VEN) 结合可能会降低死亡率,改善缓解和QOL.
- VEN组合显示出对死亡率和缓解有前景的影响,但缺乏QoL和功能状态数据.
- 低甲基化剂 (HMA) 或LDAC与VEN相结合可能会改善生存和缓解的结果.
结论:
- 有证据表明,HMA或LDAC与VEN相结合,可以提高老年AML患者的存活率和缓解率,而AML无法接受传统治疗.
- 治疗决策应纳入患者的目标和功能状态.
- 调查结果为更新的ASH-AML指南中的八项建议提供了信息.
更多相关视频
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
569
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
30.4K
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
197
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
197
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
237
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
237
01:15Drug Dosing: Geriatric Patients
227
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
227
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
188
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
232
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
232